Trial Profile
A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Adimlecleucel (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Atara Biotherapeutics
- 01 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 01 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.
- 01 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.